Infection and Chemotherapy最新文献

{"title":"Migration and the Necessity of Real-Time Locating Systems in Infection Control.","authors":"Dalmacito A Cordero","doi":"10.3947/ic.2025.0023","DOIUrl":"10.3947/ic.2025.0023","url":null,"abstract":"","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"438-439"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Use of a Real-Time Locating System in Infection Control.","authors":"Sudip Bhattacharya","doi":"10.3947/ic.2024.0147","DOIUrl":"10.3947/ic.2024.0147","url":null,"abstract":"","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"436-437"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Albumin Continues to Engender Debate.","authors":"Dae Won Park","doi":"10.3947/ic.2025.0110","DOIUrl":"10.3947/ic.2025.0110","url":null,"abstract":"","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"57 3","pages":"431-433"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145226427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Touch Me Not! Exploring the Devastating Stigma on People Living with HIV.","authors":"Dalmacito A Cordero","doi":"10.3947/ic.2025.0055","DOIUrl":"10.3947/ic.2025.0055","url":null,"abstract":"","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"444-445"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-marketing Surveillance of a Live Attenuated Herpes Zoster Vaccine (SKYZoster^®) in Adults Aged ≥50 Years in Korea.","authors":"Sun Heom Baik, Hyeeun Lee, Hyunjeong Kim, Hye Young Kim","doi":"10.3947/ic.2025.0036","DOIUrl":"10.3947/ic.2025.0036","url":null,"abstract":"<p><strong>Background: </strong>Herpes zoster (HZ; shingles) results from the reactivation of the varicella-zoster virus following a primary infection with varicella (chickenpox) in earlier life. Vaccination against HZ has been effective in preventing the disease. SKYZoster, a live attenuated zoster vaccine developed in Korea, was first licensed in Korea on September 29, 2017, and subsequently approved in Thailand (May 20, 2020) and Malaysia (December 13, 2022). This post-marketing surveillance (PMS) study aimed to assess and evaluate the safety profile of SKYZoster in adults who received the vaccine during a 4-year period in Korea.</p><p><strong>Materials and methods: </strong>This PMS study was an open, non-comparative, multi-center study conducted from September 29, 2017, to September 28, 2021. Adults aged ≥50 years who were vaccinated with SKYZoster in Korea were enrolled in this study. Adverse events (AEs) that occurred during the first 42 days after vaccination were recorded and classified using the System Organ Class and Preferred Term using MedDRA 24.1.</p><p><strong>Results: </strong>A total of 651 participants were included in the safety evaluation. Participants had a mean age of 62.15±8.59 years, with 55.30% of the participants being female and 1.69% (11 participants) had an allergy history. Overall, 121 AEs were reported in 76 participants (11.67%), including 51 adverse drug reactions (ADRs) in 37 participants (5.68%). Most AEs (120/121; 99.17%) were mild in severity and no serious AEs were reported. The most frequently reported ADRs were injection site reactions including vaccination site pain (2.92%), erythema (1.08%), and pruritus (0.46%). Multiple logistic regression analysis identified that allergy history (<i>P</i>=0.0001), concomitant medication use (<i>P</i>=0.0179) and current medical history (<i>P</i>=0.0351) were significantly associated with an increased AE incidence.</p><p><strong>Conclusion: </strong>Over a 4-year post-marketing safety evaluation period, SKYZoster exhibited an acceptable safety profile in routine clinical practice in Korea. The vaccine was well-tolerated, with no serious adverse event reported, reaffirming its role in preventing HZ in adults.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"368-377"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145076530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with HIV in Korea: 24-Month Data from BICSTaR.","authors":"Yeon-Sook Kim, Jun Yong Choi, Dae Won Park, Shin-Woo Kim, Tae Hyong Kim, Julie Ryu, Rebecca Harrison, Jeong-A Lee, Flora Park, Sun Hee Lee","doi":"10.3947/ic.2025.0061","DOIUrl":"10.3947/ic.2025.0061","url":null,"abstract":"<p><p>BICtegravir Single Tablet Regimen is a multi-national observational cohort study evaluating the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with human immunodeficiency virus. We present 24-month data from participants in Korea. Eighty-eight participants (36 treatment-naïve [TN], 52 treatment-experienced [TE]) were included. At 24 months, 100% (29/29) of TN and 100% (37/37) of TE participants had HIV-1 RNA <50 copies/mL (missing=excluded analysis). BIC/FTC/TAF persistence was 100% (33/33) and 96.1% (49/51) in TN and TE participants, respectively. Drug-related adverse events occurred in 2 TN participants. Improvements in some patient-reported outcomes were observed. BIC/FTC/TAF maintained effectiveness, persistence, and tolerability over 24 months.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"424-430"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145076541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Albumin Administration and Pulmonary Complications in Patients with Septic Shock: An Analysis Using the MIMIC-IV Database.","authors":"Jongheon Kim, Yongseop Lee, Jun Hye Seo, Jaeeun Seong, Jung Ah Lee, Jung Ho Kim, Jin Young Ahn, Su Jin Jeong, Nam Su Ku, Jun Yong Choi, Joon-Sup Yeom","doi":"10.3947/ic.2025.0048","DOIUrl":"10.3947/ic.2025.0048","url":null,"abstract":"<p><strong>Background: </strong>Albumin administration in patients with septic shock has shown potential benefits, but its association with the development of pulmonary complications remains unclear. We aimed to evaluate the impact of albumin administration on acute respiratory distress syndrome development in patients with septic shock.</p><p><strong>Materials and methods: </strong>We analyzed clinical data from the Medical Information Mart for Intensive Care IV database and included adult patients with septic shock. Propensity score matching was used to balance the covariates between the albumin and non-albumin groups. The primary outcome was the development of moderate-to-severe acute respiratory distress syndrome within 7 days. Survival analysis using the log-rank test compared acute respiratory distress syndrome development rates between the groups. Subgroup analysis was used to evaluate the effect of albumin administration on the primary outcome in various subgroups.</p><p><strong>Results: </strong>Among the 2,132 eligible patients, 1,572 (73.7%) did not receive albumin, whereas 560 (26.3%) received albumin. After propensity score matching, the primary outcome was not significantly different between the two groups (17.5% in the albumin group <i>vs.</i> 16.3% in the non-albumin group; <i>P</i>=0.708). The Kaplan-Meier curve demonstrated no difference in the primary outcome between the groups. Subgroup analysis showed no significant association between albumin administration and increased acute respiratory distress syndrome development rate across various subgroups.</p><p><strong>Conclusion: </strong>No significant difference in acute respiratory distress syndrome development was found between albumin and non-albumin groups of patients with septic shock. Albumin administration in patients with septic shock should be considered when clinically indicated, without undue concerns about acute respiratory distress syndrome development.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"378-388"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Reactogenicity and Neutralizing Antibody Responses 6 Months Post-Vaccination with Monovalent COVID-19 Vaccine.","authors":"So Yun Lim, Hye Hee Cha, Ji Yeon Kim, Ji-Soo Kwon, Euijin Chang, Seongman Bae, Jiwon Jung, Min Jae Kim, Yong Pil Chong, Sang-Ho Choi, Sang-Oh Lee, Yang Soo Kim, Sung-Han Kim","doi":"10.3947/ic.2025.0027","DOIUrl":"10.3947/ic.2025.0027","url":null,"abstract":"<p><p>The association between reactogenicity and long-term immunogenicity after coronavirus disease 2019 (COVID-19) vaccination remains unclear. This study investigated whether adverse reactions to ChAdOx1 nCoV-19 or BNT162b2 vaccines correlate with neutralizing antibody responses in severe acute respiratory syndrome coronavirus 2 infection-naïve healthcare workers. Blood samples were collected at three time points to measure neutralizing antibodies. Among 123 participants (ChAdOx1 nCoV-19, n=88; BNT162b2, n=35), local and systemic reactions were not significantly associated with antibody responses at six months post-vaccination for either vaccine type. No significant interactions between symptoms, time points, or age were observed. These findings suggest that adverse reactions might not predict long-term neutralizing antibody levels following COVID-19 vaccination.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"412-417"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511743/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitamin D Receptor Gene FokI Polymorphism in Patient with Human Immunodeficiency Virus - Tuberculosis Coinfection and Associated Risk Factors.","authors":"Anak Agung Ayu Yuli Gayatri, Ni Nyoman Ayu Dewi, I Gede Eka Wiratnaya, Ketut Tuti Parwati Merati","doi":"10.3947/ic.2025.0029","DOIUrl":"10.3947/ic.2025.0029","url":null,"abstract":"<p><strong>Background: </strong>There is still unclear method for identifying people with human immunodeficiency virus (HIV) who will develop tuberculosis (TB). This study aimed to investigate the role of vitamin D receptor (VDR) gene FokI allele f and associated risk factors in HIV-TB coinfection.</p><p><strong>Material and methods: </strong>This case control study was conducted with 60 total subjects consisting 30 subjects of HIV-TB patients as the case group and 30 subjects HIV without TB as the control. VDR gene FokI polymorphism was detected by polymerase chain reaction and sequencing, whereas light chain 3 (LC3) and caspase-3 levels were measured by enzyme-linked immunosorbent assay, and CD4 T cell by flowcytometry. Data analysis for different proportions used bivariate analysis and relationship analysis tests using logistic regression.</p><p><strong>Results: </strong>The VDR gene FokI (rs2228570) polymorphism proportion of f alleles in the case group were 26 (86.7%) and control 13 (43.3%). Low LC3 (LC3 ≤30 ng/mL) found in 27 (90.0%) of the cases and 9 of the controls (30.0%). Low caspase-3 (Caspase3 ≤3 ng/mL) found 28 (93.3%) in cases and 15 (50.0%) in the controls. The logistic regression analysis revealed that f allele of FokI VDR gene polymorphism, low LC3, low caspase-3 and low CD4 T cells are risk factors for HIV-TB co-infection as follows respectively; (odds ratio [OR], 6.921; 95% confidence interval [CI], 1.199-39.936; <i>P</i>=0.031); (OR, 16.257; 95% CI, 2.568-102.928; <i>P</i>=0.003) and (OR, 7.448; 95% CI, 0.851-65.211; <i>P</i>=0.070); (OR, 6.227; 95% CI, 0.36-37.419; <i>P</i>=0.046).</p><p><strong>Conclusion: </strong>VDR gene FokI polymorphism alleles f, low LC3, caspase-3, and low CD4 T cell count were identified as risk factors for HIV-TB Coinfection.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"349-357"},"PeriodicalIF":2.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145076532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct Out-of-Pocket Costs of Nirsevimab <i>vs.</i> Palivizumab during the First Respiratory Syncytial Virus Season: A Comparative Analysis.","authors":"Ki Wook Yun, Dayun Kang","doi":"10.3947/ic.2025.0017","DOIUrl":"10.3947/ic.2025.0017","url":null,"abstract":"<p><p>Respiratory syncytial virus (RSV) remains a significant health burden in infants, with limited prevention options. Palivizumab, the monoclonal antibody (mAb) currently used for high-risk infants, requires a five-dose regimen, costing caregivers 47,260-642,000 Korean won (KRW) under the health insurance system, depending on the remaining season and infant's weight. Nirsevimab, the first approved long-acting RSV mAb, offers season-long protection with a single dose and costs 435,000-600,000 KRW. Direct cost comparisons indicate that nirsevimab might be more economical for infants born between April and November. Policy adjustments are needed to ensure equitable RSV protection through national immunization programs.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"305-309"},"PeriodicalIF":2.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}